PURETECH HEALTH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218 GBX | +2.59% |
|
+5.57% | +12.26% |
| 04-25 | Transcript : PureTech Health plc, 2023 Earnings Call, Apr 25, 2024 | |
| 04-25 | PureTech touts "momentum" as grants shrivel but annual loss narrows | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,211 | 1,563 | 1,137 | 897.9 | 672 | 733.7 | - | - |
| Enterprise Value (EV) 1 | 1,085 | 1,234 | 723.2 | 563.2 | 672 | 378.6 | 374.1 | 16.02 |
| P/E ratio | 2.95 x | 273 x | -18.8 x | -17.9 x | -10.3 x | -3.66 x | -3.4 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 123 x | 133 x | 65.4 x | 57.5 x | 202 x | 12.5 x | 20 x | 15.5 x |
| EV / Revenue | 111 x | 105 x | 41.6 x | 36.1 x | 202 x | 6.43 x | 10.2 x | 0.34 x |
| EV / EBITDA | -8.44 x | -10.9 x | -5.06 x | -2.98 x | -4.76 x | -1.99 x | -1.82 x | - |
| EV / FCF | - | - | - | -3.03 x | - | -1.93 x | -1.89 x | - |
| FCF Yield | - | - | - | -33% | - | -51.8% | -52.9% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 285,343 | 285,830 | 287,797 | 278,566 | 271,854 | 270,209 | - | - |
| Reference price 2 | 4.243 | 5.470 | 3.950 | 3.223 | 2.472 | 2.715 | 2.715 | 2.715 |
| Announcement Date | 20-04-09 | 21-04-15 | 22-04-26 | 23-04-28 | 24-04-25 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.807 | 11.77 | 17.39 | 15.62 | 3.33 | 58.9 | 36.75 | 47.2 |
| EBITDA 1 | -128.6 | -112.9 | -143 | -188.9 | -141.3 | -190 | -206 | - |
| EBIT 1 | -135.4 | -119.5 | -150.3 | -197.8 | -146.2 | -212.4 | -228.7 | - |
| Operating Margin | -1,380.64% | -1,015.73% | -864.29% | -1,266.53% | -4,390.36% | -360.61% | -622.31% | - |
| Earnings before Tax (EBT) 1 | 478.5 | 18.97 | -58.95 | -92.78 | -36.1 | -213 | -229 | - |
| Net income 1 | 421.1 | 5.985 | -60.56 | -50.35 | -65.7 | -144.7 | -191 | -252.6 |
| Net margin | 4,294.32% | 50.86% | -348.27% | -322.41% | -1,972.88% | -245.67% | -519.86% | -535.17% |
| EPS 2 | 1.440 | 0.0200 | -0.2100 | -0.1800 | -0.2400 | -0.7410 | -0.7980 | - |
| Free Cash Flow 1 | - | - | - | -186 | - | -196.1 | -197.9 | - |
| FCF margin | - | - | - | -1,190.73% | - | -332.94% | -538.5% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-04-09 | 21-04-15 | 22-04-26 | 23-04-28 | 24-04-25 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.42 | 6.844 | 4.924 | 5.836 | 11.55 | 7.03 | 8.588 | 3.15 | 0.18 | 7.5 | 110.3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | -65.08 | -52.3 | -66.75 | -68.08 | -82.2 | -101.2 | - | -76.16 | - | - | - |
| Operating Margin | -1,200.77% | -764.17% | -1,355.58% | -1,166.55% | -711.58% | -1,439.43% | - | -2,417.87% | - | - | - |
| Earnings before Tax (EBT) | 467.4 | 174.5 | -155.5 | -94.93 | 35.98 | -55.96 | - | -13.74 | - | - | - |
| Net income 1 | 392.8 | 124 | -118 | -75.4 | 14.84 | -28.34 | -22.01 | -25 | -40.69 | -83.5 | 7 |
| Net margin | 7,247.27% | 1,811.18% | -2,395.86% | -1,291.9% | 128.44% | -403.19% | -256.29% | -793.78% | -22,607.22% | -1,113.33% | 6.35% |
| EPS | - | 0.4200 | -0.4000 | - | - | -0.1000 | - | -0.0900 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 20-04-09 | 20-08-27 | 21-04-15 | 21-08-24 | 22-04-26 | 22-08-25 | 23-04-28 | 23-08-29 | 24-04-25 | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 125 | 329 | 414 | 335 | - | 355 | 360 | 718 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -186 | - | -196 | -198 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -62.6% | -98.4% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | -0.3400 | -0.4500 | -0.5500 | -0.6300 | - | -0.6600 | -0.6600 | - |
| Capex 1 | 12.1 | 5.17 | - | 7.18 | - | 7.1 | 7.2 | - |
| Capex / Sales | 123.77% | 43.93% | - | 45.95% | - | 12.05% | 19.59% | - |
| Announcement Date | 20-04-09 | 21-04-15 | 22-04-26 | 23-04-28 | 24-04-25 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.715
USD
Average target price
6.205
USD
Spread / Average Target
+128.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.26% | 734M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PRTC Stock
- Financials PureTech Health plc
